Jameel Al-Tamimi | Biopharmaceutics | Best Researcher Award

Jameel Al-Tamimi | Biopharmaceutics | Best Researcher Award

Dr. Jameel Al-Tamimi, King Saud University, Saudi Arabia

Dr. Jameel Al-Tamimi is a distinguished researcher with a Ph.D. in Immunogenetics from King Saud University, Riyadh, Saudi Arabia. His research focuses on immunology, particularly the role of Killer Immunoglobulin-like Receptors (KIRs) in leukemia. He has expertise in molecular techniques, immunology, and forensic entomology. Dr. Al-Tamimi has published numerous research articles and has contributed to various academic committees. His teaching experience spans courses in molecular biology, human physiology, and medical entomology.

Publication Profile

Google Scholar

Education

Dr. Jameel Al-Tamimi 🎓 is a distinguished researcher with a Ph.D. in Immunogenetics (Excellent 4.9/5) from King Saud University, where his thesis explored the Role of Killer Immunoglobulin-like Receptors (KIRs) with HLA Ligands in Saudi Leukemia Patients 🧬. He also holds an M.Sc. in Entomology and Parasitology (Excellent 4.9/5), investigating the anti-inflammatory effects of Pachycondyla sennaarensis (Samsum Ant) venom in male albino rats 🐜🧪. Dr. Al-Tamimi earned his B.Sc. in Biology (Very Good 89.9/100) from Thamar University, Yemen, with research focused on physiological changes in viral hepatitis (HbsAg and HCV) patients at Thamar Hospital 🧫🦠.

Experience

Dr. Jameel Al-Tamimi 🧑‍🔬 brings a wealth of academic and research experience. Since 2023, he has served on the Scientific Committee for the Researcher Support Program (RSPD) and Research Groups Program (RGP) at the Deanship of Scientific Research 📚. At King Saud University, he contributed to key committees, including labs, academic accreditation, exams, and graduate studies 🏛️. He supervised both the endocrinology and immunology laboratories 🧪 and mentored undergraduate and master’s students 🎓. Skilled in handling rats, mice, and insects 🐭🦗, Dr. Al-Tamimi is also proficient in advanced molecular biology, immunology, and physiology techniques 🧬🔬.

Awards

Dr. Jameel Al-Tamimi 🎓 has been recognized for his academic excellence with several prestigious awards. In 2015, he received an acknowledgment certificate from the Chairman of the Center of Excellence in the Development of Science and Mathematics Education at King Saud University 🏅, highlighting his contribution to scientific advancement. Earlier, in 2013, he was honored with a Certificate of Appreciation (General Prize) during the first Graduate Student Annual Scientific Meeting at KSU 📜🎉. These achievements reflect his dedication to academic excellence, innovation in research, and commitment to the scientific community 🌟📚.

Research Focus

Dr. Jameel Al-Tamimi is a multidisciplinary biomedical researcher whose primary focus lies in oxidative stress, wound healing, diabetes, and nanoparticle therapeutics. His work spans nanomedicine, immunomodulation, and natural product pharmacology, particularly in evaluating the biological activities of camel milk peptides, selenium and zinc oxide nanoparticles, and bioactive plant extracts. Dr. Al-Tamimi’s studies contribute significantly to redox biology, diabetic complications, and biofabrication of therapeutic agents, offering innovative strategies for combating chronic diseases and enhancing healing processes. 🧫💊🐫 His collaborative work reflects a strong emphasis on toxicology, regenerative medicine, and bio-nanotechnology.

Publication Top Notes

Camel milk peptide improves wound healing in diabetic rats by orchestrating the redox status and immune response

Wound healing of different molecular weight of hyaluronan; in-vivo study

Folic acid and melatonin mitigate diabetic nephropathy in rats via inhibition of oxidative stress

Synthesis, structural characterization of silver (I)-NHC complexes and their antimicrobial, antioxidant and antitumor activities

Potential effects of the combination of nicotinamide, vitamin B2 and vitamin C on oxidative-mediated hepatotoxicity induced by thioacetamide

Efficacy of a Methanolic Extract of Adansonia digitata Leaf in Alleviating Hyperglycemia, Hyperlipidemia, and Oxidative Stress of Diabetic Rats

Antioxidant Bioactivity of Samsum Ant (Pachycondyla sennaarensis) Venom Protects against CCL4‐Induced Nephrotoxicity in Mice

Biofabrication of Zinc Oxide Nanoparticle from Ochradenus baccatus Leaves: Broad‐Spectrum Antibiofilm Activity, Protein Binding Studies, and In Vivo Toxicity …

Yu Liu | Drug Discovery and Development | Best Researcher Award

Yu Liu | Drug Discovery and Development | Best Researcher Award

Mr. Yu Liu, China Institute of Pharmaceutical Industry Co., Ltd, China

Dr. Liu Yu (b. January 11, 1981, Hengyang, Hunan) is a distinguished researcher and doctoral supervisor specializing in medicinal chemistry. He earned his Ph.D. from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (2011). Currently, he serves as Deputy Director at the China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center. He is also a standing committee member of the Health Economics Theory and Policy Committee. Dr. Liu plays a pivotal role in pharmaceutical research and technology transfer in China.

Publication Profile

Scopus

Education

Mr. Yu Liu pursued his education in Medicinal Chemistry 🧪 at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences 🎓. He was enrolled as a full-time student from September 2008 to July 2011 📅. During this period, he dedicated himself to advanced research in the field, ultimately earning a Doctorate degree 🎖️. His studies focused on the development of medicinal compounds and pharmaceutical innovations, contributing to the field of drug discovery and development 💊. With a strong academic foundation, Mr. Liu gained expertise in chemical synthesis and pharmacology, preparing him for a successful career in medicinal sciences 🔬.

Professional Leadership

Mr. Yu Liu serves as the Deputy Director 🏛️ at both the Technology Transfer Center, China National Institute for the Control of Pharmaceutical and Biological Products and the Shanghai Drug Synthesis Process Engineering Technology Research Center 🔬. In these roles, he plays a pivotal part in advancing pharmaceutical and biotechnology research 💊. His leadership drives innovation in drug development and synthesis, ensuring progress in the field of medicinal chemistry 🧪. With his extensive expertise, Mr. Liu significantly contributes to technology transfer, regulatory advancements, and pharmaceutical innovation, reinforcing his influence in the global healthcare industry 🌍.

Experience

Mr. Yu Liu is an esteemed member of high-level academic committees 🏛️, including the Standing Committee of the Health Economics Theory and Policy Professional Committee under the Chinese Association of Health Economics 📊. His active participation in these organizations reflects his dedication to bridging scientific innovation and economic policy in healthcare 💡💰. By contributing to policy development and strategic decision-making, he plays a crucial role in shaping the future of health economics and pharmaceutical advancements 💊. His interdisciplinary expertise ensures a significant impact on both scientific research and economic frameworks, fostering innovation in healthcare systems 🌍.

Research Focus

Yu Liu’s research focuses on analytical chemistry, particularly in pharmaceutical analysis. His expertise lies in the development and validation of advanced chromatographic techniques, such as GC (Gas Chromatography) and HPLC-RID (High-Performance Liquid Chromatography with Refractive Index Detection). His work involves identifying and quantifying related substances in pharmaceutical compounds, including novel impurities in tetrabenazine. His contributions ensure drug purity, safety, and efficacy, making a significant impact on quality control and regulatory compliance in the pharmaceutical industry. His research bridges analytical chemistry and pharmaceutical sciences, advancing drug formulation and safety.

Publication Top Notes

GC and HPLC-RID method development and validation for the determination of twelve related substances, including several novel compounds in tetrabenazine